Research outputs
2025
Re-emergence of circulating non-malignant B cells as a prognostic biomarker in chronic lymphocytic leukaemia
Lim, Y. J., Duckworth, A., Clarke, K., Oates, M., Karpha, I., Gornall, M., . . . Pettitt, A. (2025). Re-emergence of circulating non-malignant B cells as a prognostic biomarker in chronic lymphocytic leukaemia. SCIENTIFIC REPORTS, 15(1). doi:10.1038/s41598-025-16558-5
Real world epidemiological trends in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), England 2014-2021: Preliminary data from the uncover Study group
Karpha, I., Akter, N., Erinfolami, T., Abdulkareem, T., Lim, Y. J., Renshaw, H., . . . McKay, P. (2025). Real world epidemiological trends in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), England 2014-2021: Preliminary data from the uncover Study group. BLOOD, 146, 6298-6299. doi:10.1182/blood-2025-6298
Respiratory syncytial virus (RSV) infection in adults with blood cancer: An England-wide population study
Lim, Y. J., Erinfolami, T., Akter, N., Abdulkareem, T., Ross, A., Johnston, B., . . . Pettitt, A. (2025). Respiratory syncytial virus (RSV) infection in adults with blood cancer: An England-wide population study. BLOOD, 146, 6402-6403. doi:10.1182/blood-2025-6402
The impact of frailty on real world outcomes for multiple myeloma patients in England - a cohort study from the uncover study group and ukmra frailty group.
Chandler, T., Karpha, I., Akter, N., Erinfolami, T., Liu, H., Johnston, B., . . . Cook, G. (2025). The impact of frailty on real world outcomes for multiple myeloma patients in England - a cohort study from the uncover study group and ukmra frailty group.. BLOOD, 146, 2792-2793. doi:10.1182/blood-2025-2792
Treatment intensity and region of diagnosis affect survival in primary CNS lymphoma in England: A national cohort study from the uncover project
Bishton, M., Akter, N., Karpha, I., Tayabali, S., Erinfolami, T., Smith, C. T., . . . Fox, C. (2025). Treatment intensity and region of diagnosis affect survival in primary CNS lymphoma in England: A national cohort study from the uncover project. BLOOD, 146, 6325-6326. doi:10.1182/blood-2025-6325
Frailty and Social Deprivation Affect Real-World Outcomes in Multiple Myeloma (MM) – an England-Wide Cohort Study from the UNCOVER Study Group and UKMRA Frailty Group
Chandler, T., Karpha, I., Akter, N., Erinfolami, T., Liu, H., Johnston, B., . . . Cook, G. (2025). Frailty and Social Deprivation Affect Real-World Outcomes in Multiple Myeloma (MM) – an England-Wide Cohort Study from the UNCOVER Study Group and UKMRA Frailty Group. Clinical Lymphoma Myeloma and Leukemia, 25, S264-S265. doi:10.1016/s2152-2650(25)03845-5
331 | INCIDENCE AND SURVIVAL OF PRIMARY CNS LYMPHOMA: AN ENGLAND‐WIDE COHORT STUDY FROM THE UNCOVER STUDY GROUP
Karpha, I., Tayabali, S., Akter, N., Erinfolami, T., Smith, C. T., Liu, H., . . . Bishton, M. (2025). 331 | INCIDENCE AND SURVIVAL OF PRIMARY CNS LYMPHOMA: AN ENGLAND‐WIDE COHORT STUDY FROM THE UNCOVER STUDY GROUP. Hematological Oncology, 43(S3). doi:10.1002/hon.70094_331
481 | ADAPTIVE RESISTANCE IN LYMPHOPROLIFERATIVE DISORDERS: POTENTIAL ROLES OF SNHG32, A NOVEL NON‐CODING TUMOUR SUPPRESSOR
Karpha, I., Glenn, M., Ross, A., van Kampen, F., Duckworth, A., Lim, Y. J., . . . Kalakonda, N. (2025). 481 | ADAPTIVE RESISTANCE IN LYMPHOPROLIFERATIVE DISORDERS: POTENTIAL ROLES OF SNHG32, A NOVEL NON‐CODING TUMOUR SUPPRESSOR. Hematological Oncology, 43(S3). doi:10.1002/hon.70096_481
Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia
Lim, Y. J., Duckworth, A. D., Clarke, K., Kennedy, P., Karpha, I., Oates, M., . . . Pettitt, A. R. (2025). Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia. Frontiers in Immunology, 16. doi:10.3389/fimmu.2025.1528405
2024
HIGH DIMENSIONAL MASS CYTOMETRY ANALYSIS OF NON-MALIGNANT IMMUNE POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
Lim, Y. (2024, October 25). HIGH DIMENSIONAL MASS CYTOMETRY ANALYSIS OF NON-MALIGNANT IMMUNE POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA.
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Lim, Y. J., Ward, V., Brown, A., Phillips, E., Kronsteiner, B., Malone, T., . . . Pettitt, A. (2024). Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.. British journal of haematology, 205(2), 440-451. doi:10.1111/bjh.19562
Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity
Kennedy, P. T., Saulters, E. L., Duckworth, A. D., Lim, Y. J., Woolley, J. F., Slupsky, J. R., . . . Dahal, L. N. (2024). Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. MOLECULAR THERAPY, 32(2), 457-468. doi:10.1016/j.ymthe.2023.11.028
2023
Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL)
Lim, Y. J., Duckworth, A., Clarke, K., Kennedy, P., Oates, M., Gornall, M., . . . Pettitt, A. (2023). Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL). BLOOD, 142. doi:10.1182/blood-2023-185091
High Dimensional Detection of Non-Malignant B-Cells and Its Clinical Implications in Patients with Chronic Lymphocytic Leukaemia (CLL) Undergoing Frontline Therapy
Lim, Y. J., Duckworth, A., Clarke, K., Oates, M., Gornall, M., Kalakonda, N., . . . Pettitt, A. (2023). High Dimensional Detection of Non-Malignant B-Cells and Its Clinical Implications in Patients with Chronic Lymphocytic Leukaemia (CLL) Undergoing Frontline Therapy. BLOOD, 142. doi:10.1182/blood-2023-185018
Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL)
Lim, Y. J., Duckworth, A., Clarke, K., Oates, M., Gornall, M., Kalakonda, N., . . . Pettitt, A. (2023). Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL). BLOOD, 142. doi:10.1182/blood-2023-185063
P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
Jer Lim, Y., Ward, V., Farrell, L., Naisbitt, D., Brown, A., Phillips, E., . . . Pettitt, A. (2023). P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY. HemaSphere, 7(S3), e49729ac. doi:10.1097/01.hs9.0000971276.49729.ac
P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
Jer Lim, Y., Ward, V., Farrell, L., Naisbitt, D., Brown, A., Phillips, E., . . . Pettitt, A. (2023). P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY. HemaSphere, 7(Suppl ).
2022
COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis
Lim, Y. J., Khan, U., Karpha, I., Ross, A., Saif, M., Remberger, M., . . . Floisand, Y. (2022). COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis. EJHAEM, 3(3), 862-872. doi:10.1002/jha2.465
2021
Autologous Hematopoietic Stem Cell Transplantation for Behcet's Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
Puyade, M., Patel, A., Lim, Y. J., Blank, N., Badoglio, M., Gualandi, F., . . . Snowden, J. A. (2021). Autologous Hematopoietic Stem Cell Transplantation for Behcet's Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. In FRONTIERS IN IMMUNOLOGY Vol. 12. doi:10.3389/fimmu.2021.638709
2020
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival
Martinez-Calle, N., Poynton, E., Alchawaf, A., Kassam, S., Horan, M., Rafferty, M., . . . Cwynarski, K. (2020). Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. BRITISH JOURNAL OF HAEMATOLOGY, 190(3), 394-404. doi:10.1111/bjh.16592
Gastrointestinal system
On, W. H., Lim, Y. J., & Yap, K. (2020). Gastrointestinal system. In Applied Anatomy Physiology an Interdisciplinary Approach (pp. 329-348). doi:10.1016/B978-0-7295-4319-4.00018-4
2019
Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival
Poynton, E., Martinez-Calle, N., Alchawaf, A., Kassam, S., Horan, M., Rafferty, M., . . . Fox, C. (2019). Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 28-29). Retrieved from https://www.webofscience.com/
2018
Long-Term Safety and Efficacy of Autologous or Allogeneic Donor Stem Cell Transplantation in Patients with Behcet's Syndrome
Patel, A., & Lim, Y. J. (2018). Long-Term Safety and Efficacy of Autologous or Allogeneic Donor Stem Cell Transplantation in Patients with Behcet's Syndrome. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-115815
Randomized Trials of Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Systematic Review and Meta-Analysis with Trial Sequential Analysis of Overall Mortality
Patel, A., & Lim, Y. J. (2018). Randomized Trials of Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Systematic Review and Meta-Analysis with Trial Sequential Analysis of Overall Mortality. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-115326
Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival
Martinez-Calle, N., Poynton, E., Alchawaf, A., Kassam, S., Horan, M., Rafferty, M., . . . Cwynarski, K. (2018). Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-111901
Ruxolitinib in Myelofibrosis: a multicentre experience in England, Northern Ireland and Wales
Russell, J., Daly, A., Fisken, R., Dicu, A., Cunningham, J., Sparksman, D., . . . Sadullah, S. (2018). Ruxolitinib in Myelofibrosis: a multicentre experience in England, Northern Ireland and Wales. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 10). Retrieved from https://www.webofscience.com/
Utility of 18F-FDG PET/CT in the diagnosis and assessment of myeloma associated bone disease: a single centre experience
Lim, Y. J., Taheri, A., Fernando, R., Seshadri, N., Brearton, G., & Hawkins, S. (2018). Utility of 18F-FDG PET/CT in the diagnosis and assessment of myeloma associated bone disease: a single centre experience. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 105-106). Retrieved from https://www.webofscience.com/
2017
Treatment of newly diagnosed central nervous system (<scp>CNS</scp>) lymphoma patients based on co‐morbidities & performance status: A single‐centre experience
Lim, Y., & Smith, J. (2017). Treatment of newly diagnosed central nervous system (<scp>CNS</scp>) lymphoma patients based on co‐morbidities & performance status: A single‐centre experience. Hematological Oncology, 35(S2), 352-353. doi:10.1002/hon.2439_104
TREATMENT OF NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS BASED ON COMORBIDITIES & PERFORMANCE STATUS: A SINGLE-CENTRE EXPERIENCE
Lim, Y. J., & Smith, J. (2017). TREATMENT OF NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS BASED ON COMORBIDITIES & PERFORMANCE STATUS: A SINGLE-CENTRE EXPERIENCE. In HAEMATOLOGICA Vol. 102 (pp. 699). Retrieved from https://www.webofscience.com/